Consolidated Balance Sheets - USD ($) $ in Thousands		Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents		$ 26,120	$ 124,553
Restricted cash		2,001	0
Marketable securities		20,988	52,768
Accounts receivable, net of allowance for doubtful accounts of $1,037 and $226, respectively		34,430	28,531
Other receivables		1,787	375
Inventories		41,160	27,860
Prepaid expenses and other current assets		3,359	2,325
Total current assets		129,845	236,412
Property and equipment, net		23,265	23,355
Goodwill	[1]	120,711	28,685
Intangibles, net		84,511	42,118
Deposits and other assets		1,352	480
Total assets		359,684	331,050
Current liabilities:
Accounts payable		13,237	17,549
Accrued payroll		19,997	13,030
Accrued expenses and other current liabilities		11,668	5,576
Contingently issuable common stock		0	14,700
Total current liabilities		44,902	50,855
Deferred income taxes		879	879
Deferred rent		7,949	8,051
Other liabilities		3,783	210
Contingently issuable common stock		12,200	0
Convertible notes		177,178	167,748
Total liabilities		246,891	227,743
Commitments and contingencies
Stockholders’ equity:
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized. No shares issued and outstanding.		0	0
Common stock, $0.001 par value; 135,000,000 and 100,000,000 shares authorized, respectively. 82,986,244 and 68,235,179 shares issued, respectively. 82,774,005 and 68,034,386 shares outstanding, respectively.		83	68
Additional paid-in capital		567,765	404,462
Accumulated deficit		(453,601)	(298,924)
Treasury stock, at cost, 212,239 and 200,793 shares, respectively.		(2,942)	(2,809)
Accumulated other comprehensive income		1,488	510
Total stockholders’ equity		112,793	103,307
Total liabilities and stockholders’ equity		$ 359,684	$ 331,050

[1] Difference in the value between these dates is mainly due to acquisition of TriVascular. Refer to Note 13 of the consolidated financial statements for further discussion.